Models:
Philip Bordner
philipB/
NER-medical-text
0
Downloads: 1
Diff of /html_files/28250304.html [000000] .. [c0f169]

Switch to unified view

a b/html_files/28250304.html 

  1
  





  
  

  2
  
    <!DOCTYPE html>





  
  

  3
  
    <html>





  
  

  4
  
    <head>





  
  

  5
  
        <meta charset="utf-8">





  
  

  6
  
        <title>28250304 Visualization</title>





  
  

  7
  
    </head>





  
  

  8
  
    <body>





  
  

  9
  
        <h1>28250304 Visualization</h1>





  
  

  10
  
        <p><a href="main.html">Back to Main Page</a></p>





  
  

  11
  
        <div class="entities" style="line-height: 2.5; direction: ltr">A 





  
  

  12
  
<mark class="entity" style="background: #f6c3d0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  13
  
    44





  
  

  14
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Age</span>





  
  

  15
  
</mark>





  
  

  16
  
-





  
  

  17
  
<mark class="entity" style="background: #f6c3d0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  18
  
    year





  
  

  19
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Age</span>





  
  

  20
  
</mark>





  
  

  21
  
-





  
  

  22
  
<mark class="entity" style="background: #f6c3d0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  23
  
    old





  
  

  24
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Age</span>





  
  

  25
  
</mark>





  
  

  26
  
 





  
  

  27
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  28
  
    man





  
  

  29
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sex</span>





  
  

  30
  
</mark>





  
  

  31
  
 had been 





  
  

  32
  
<mark class="entity" style="background: #77c5d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  33
  
    diagnosed





  
  

  34
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Clinical_event</span>





  
  

  35
  
</mark>





  
  

  36
  
 with 





  
  

  37
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  38
  
    LCNEC





  
  

  39
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  40
  
</mark>





  
  

  41
  
 of the 





  
  

  42
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  43
  
    thymus





  
  

  44
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  45
  
</mark>





  
  

  46
  
 with 





  
  

  47
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  48
  
    bone





  
  

  49
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  50
  
</mark>





  
  

  51
  
 





  
  

  52
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  53
  
    metastasis





  
  

  54
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  55
  
</mark>





  
  

  56
  
 at a 





  
  

  57
  
<mark class="entity" style="background: #f7a399; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  58
  
    different





  
  

  59
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Nonbiological_location</span>





  
  

  60
  
</mark>





  
  

  61
  
 





  
  

  62
  
<mark class="entity" style="background: #f7a399; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  63
  
    hospital





  
  

  64
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Nonbiological_location</span>





  
  

  65
  
</mark>





  
  

  66
  
 





  
  

  67
  
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  68
  
    3





  
  

  69
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span>





  
  

  70
  
</mark>





  
  

  71
  
 





  
  

  72
  
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  73
  
    years





  
  

  74
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span>





  
  

  75
  
</mark>





  
  

  76
  
 





  
  

  77
  
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  78
  
    previously





  
  

  79
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span>





  
  

  80
  
</mark>





  
  

  81
  
.</br>The serum levels of 





  
  

  82
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  83
  
    ACTH





  
  

  84
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  85
  
</mark>





  
  

  86
  
 and 





  
  

  87
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  88
  
    cortisol





  
  

  89
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  90
  
</mark>





  
  

  91
  
 were 





  
  

  92
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  93
  
    elevated





  
  

  94
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  95
  
</mark>





  
  

  96
  
, but 





  
  

  97
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  98
  
    brain





  
  

  99
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  100
  
</mark>





  
  

  101
  
 





  
  

  102
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  103
  
    magnetic





  
  

  104
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  105
  
</mark>





  
  

  106
  
 





  
  

  107
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  108
  
    resonance





  
  

  109
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  110
  
</mark>





  
  

  111
  
 





  
  

  112
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  113
  
    imaging





  
  

  114
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  115
  
</mark>





  
  

  116
  
 revealed that his 





  
  

  117
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  118
  
    pituitary





  
  

  119
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  120
  
</mark>





  
  

  121
  
 





  
  

  122
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  123
  
    gland





  
  

  124
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  125
  
</mark>





  
  

  126
  
 was 





  
  

  127
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  128
  
    normal





  
  

  129
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  130
  
</mark>





  
  

  131
  
.</br>However, 





  
  

  132
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  133
  
    immunohistochemical





  
  

  134
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  135
  
</mark>





  
  

  136
  
 





  
  

  137
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  138
  
    staining





  
  

  139
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  140
  
</mark>





  
  

  141
  
 of the 





  
  

  142
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  143
  
    thymic





  
  

  144
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  145
  
</mark>





  
  

  146
  
 





  
  

  147
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  148
  
    tumor





  
  

  149
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  150
  
</mark>





  
  

  151
  
 





  
  

  152
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  153
  
    tissue





  
  

  154
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  155
  
</mark>





  
  

  156
  
 revealed 





  
  

  157
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  158
  
    partial





  
  

  159
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  160
  
</mark>





  
  

  161
  
 





  
  

  162
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  163
  
    anti





  
  

  164
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  165
  
</mark>





  
  

  166
  
-





  
  

  167
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  168
  
    ACTH





  
  

  169
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  170
  
</mark>





  
  

  171
  
 





  
  

  172
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  173
  
    antibody





  
  

  174
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  175
  
</mark>





  
  

  176
  
 





  
  

  177
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  178
  
    positivity





  
  

  179
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  180
  
</mark>





  
  

  181
  
.</br>The 





  
  

  182
  
<mark class="entity" style="background: #e3b5a4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  183
  
    tumor





  
  

  184
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Coreference</span>





  
  

  185
  
</mark>





  
  

  186
  
 was therefore determined to be 





  
  

  187
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  188
  
    ectopically





  
  

  189
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  190
  
</mark>





  
  

  191
  
 





  
  

  192
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  193
  
    producing





  
  

  194
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  195
  
</mark>





  
  

  196
  
 





  
  

  197
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  198
  
    ACTH





  
  

  199
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  200
  
</mark>





  
  

  201
  
.</br>The patient underwent 





  
  

  202
  
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  203
  
    chemotherapy





  
  

  204
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span>





  
  

  205
  
</mark>





  
  

  206
  
 with 





  
  

  207
  
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  208
  
    cisplatin





  
  

  209
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span>





  
  

  210
  
</mark>





  
  

  211
  
 and 





  
  

  212
  
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  213
  
    irinotecan





  
  

  214
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span>





  
  

  215
  
</mark>





  
  

  216
  
, but the continuation of chemotherapy was 





  
  

  217
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  218
  
    problematic





  
  

  219
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  220
  
</mark>





  
  

  221
  
 





  
  

  222
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  223
  
    due





  
  

  224
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  225
  
</mark>





  
  

  226
  
 





  
  

  227
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  228
  
    to





  
  

  229
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  230
  
</mark>





  
  

  231
  
 





  
  

  232
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  233
  
    a





  
  

  234
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  235
  
</mark>





  
  

  236
  
 





  
  

  237
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  238
  
    lack





  
  

  239
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  240
  
</mark>





  
  

  241
  
 





  
  

  242
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  243
  
    of





  
  

  244
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  245
  
</mark>





  
  

  246
  
 





  
  

  247
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  248
  
    tolerance





  
  

  249
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  250
  
</mark>





  
  

  251
  
.</br>Treatment for 





  
  

  252
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  253
  
    hypertension





  
  

  254
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  255
  
</mark>





  
  

  256
  
 and 





  
  

  257
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  258
  
    diabetes





  
  

  259
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  260
  
</mark>





  
  

  261
  
 caused by the 





  
  

  262
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  263
  
    ectopic





  
  

  264
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  265
  
</mark>





  
  

  266
  
 





  
  

  267
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  268
  
    ACTH





  
  

  269
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  270
  
</mark>





  
  

  271
  
 





  
  

  272
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  273
  
    syndrome





  
  

  274
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  275
  
</mark>





  
  

  276
  
 was initiated, as was treatment with 





  
  

  277
  
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  278
  
    zoledronic





  
  

  279
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span>





  
  

  280
  
</mark>





  
  

  281
  
 





  
  

  282
  
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  283
  
    acid





  
  

  284
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span>





  
  

  285
  
</mark>





  
  

  286
  
 for 





  
  

  287
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  288
  
    bone





  
  

  289
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  290
  
</mark>





  
  

  291
  
 





  
  

  292
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  293
  
    metastasis





  
  

  294
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  295
  
</mark>





  
  

  296
  
.</br>The patient was 





  
  

  297
  
<mark class="entity" style="background: #77c5d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  298
  
    referred





  
  

  299
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Clinical_event</span>





  
  

  300
  
</mark>





  
  

  301
  
 to the 





  
  

  302
  
<mark class="entity" style="background: #f7a399; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  303
  
    Endocrine





  
  

  304
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Nonbiological_location</span>





  
  

  305
  
</mark>





  
  

  306
  
 





  
  

  307
  
<mark class="entity" style="background: #f7a399; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  308
  
    Center





  
  

  309
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Nonbiological_location</span>





  
  

  310
  
</mark>





  
  

  311
  
 





  
  

  312
  
<mark class="entity" style="background: #f7a399; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  313
  
    at





  
  

  314
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Nonbiological_location</span>





  
  

  315
  
</mark>





  
  

  316
  
 





  
  

  317
  
<mark class="entity" style="background: #f7a399; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  318
  
    our





  
  

  319
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Nonbiological_location</span>





  
  

  320
  
</mark>





  
  

  321
  
 





  
  

  322
  
<mark class="entity" style="background: #f7a399; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  323
  
    hospital





  
  

  324
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Nonbiological_location</span>





  
  

  325
  
</mark>





  
  

  326
  
 





  
  

  327
  
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  328
  
    after





  
  

  329
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span>





  
  

  330
  
</mark>





  
  

  331
  
 





  
  

  332
  
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  333
  
    3





  
  

  334
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span>





  
  

  335
  
</mark>





  
  

  336
  
 





  
  

  337
  
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  338
  
    months





  
  

  339
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span>





  
  

  340
  
</mark>





  
  

  341
  
 due to a 





  
  

  342
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  343
  
    sensation





  
  

  344
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  345
  
</mark>





  
  

  346
  
 





  
  

  347
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  348
  
    of





  
  

  349
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  350
  
</mark>





  
  

  351
  
 





  
  

  352
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  353
  
    weakness





  
  

  354
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  355
  
</mark>





  
  

  356
  
 and the worsening of his 





  
  

  357
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  358
  
    hyperglycemia





  
  

  359
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  360
  
</mark>





  
  

  361
  
.</br>A 





  
  

  362
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  363
  
    physical





  
  

  364
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  365
  
</mark>





  
  

  366
  
 





  
  

  367
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  368
  
    examination





  
  

  369
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  370
  
</mark>





  
  

  371
  
 revealed 





  
  

  372
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  373
  
    hypertension





  
  

  374
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  375
  
</mark>





  
  

  376
  
, a 





  
  

  377
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  378
  
    subcutaneous





  
  

  379
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  380
  
</mark>





  
  

  381
  
 





  
  

  382
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  383
  
    mass





  
  

  384
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  385
  
</mark>





  
  

  386
  
 that was 





  
  

  387
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  388
  
    palpable





  
  

  389
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  390
  
</mark>





  
  

  391
  
 in the 





  
  

  392
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  393
  
    anterior





  
  

  394
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  395
  
</mark>





  
  

  396
  
 





  
  

  397
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  398
  
    chest





  
  

  399
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  400
  
</mark>





  
  

  401
  
, and 





  
  

  402
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  403
  
    redness





  
  

  404
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  405
  
</mark>





  
  

  406
  
 and 





  
  

  407
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  408
  
    swelling





  
  

  409
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  410
  
</mark>





  
  

  411
  
 of the 





  
  

  412
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  413
  
    left





  
  

  414
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  415
  
</mark>





  
  

  416
  
 





  
  

  417
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  418
  
    lower





  
  

  419
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  420
  
</mark>





  
  

  421
  
 





  
  

  422
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  423
  
    leg





  
  

  424
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  425
  
</mark>





  
  

  426
  
 without 





  
  

  427
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  428
  
    fever





  
  

  429
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  430
  
</mark>





  
  

  431
  
, 





  
  

  432
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  433
  
    respiratory





  
  

  434
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  435
  
</mark>





  
  

  436
  
 





  
  

  437
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  438
  
    symptoms





  
  

  439
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  440
  
</mark>





  
  

  441
  
, 





  
  

  442
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  443
  
    hypoxemia





  
  

  444
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  445
  
</mark>





  
  

  446
  
, or 





  
  

  447
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  448
  
    abnormal





  
  

  449
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  450
  
</mark>





  
  

  451
  
 





  
  

  452
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  453
  
    chest





  
  

  454
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  455
  
</mark>





  
  

  456
  
 





  
  

  457
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  458
  
    sounds





  
  

  459
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  460
  
</mark>





  
  

  461
  
.</br>The 





  
  

  462
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  463
  
    oxygen





  
  

  464
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  465
  
</mark>





  
  

  466
  
 





  
  

  467
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  468
  
    saturation





  
  

  469
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  470
  
</mark>





  
  

  471
  
 by 





  
  

  472
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  473
  
    pulse





  
  

  474
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  475
  
</mark>





  
  

  476
  
 





  
  

  477
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  478
  
    oximeter





  
  

  479
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  480
  
</mark>





  
  

  481
  
 in 





  
  

  482
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  483
  
    room





  
  

  484
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  485
  
</mark>





  
  

  486
  
 





  
  

  487
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  488
  
    air





  
  

  489
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  490
  
</mark>





  
  

  491
  
 and was 





  
  

  492
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  493
  
    97%





  
  

  494
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  495
  
</mark>





  
  

  496
  
 and his 





  
  

  497
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  498
  
    respiratory





  
  

  499
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  500
  
</mark>





  
  

  501
  
 





  
  

  502
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  503
  
    rate





  
  

  504
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  505
  
</mark>





  
  

  506
  
 was 





  
  

  507
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  508
  
    13





  
  

  509
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  510
  
</mark>





  
  

  511
  
 





  
  

  512
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  513
  
    breaths





  
  

  514
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  515
  
</mark>





  
  

  516
  
 





  
  

  517
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  518
  
    per





  
  

  519
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  520
  
</mark>





  
  

  521
  
 





  
  

  522
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  523
  
    minute





  
  

  524
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  525
  
</mark>





  
  

  526
  
.</br>Among the 





  
  

  527
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  528
  
    laboratory





  
  

  529
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  530
  
</mark>





  
  

  531
  
 





  
  

  532
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  533
  
    findings





  
  

  534
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  535
  
</mark>





  
  

  536
  
, the 





  
  

  537
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  538
  
    white





  
  

  539
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  540
  
</mark>





  
  

  541
  
 





  
  

  542
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  543
  
    blood





  
  

  544
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  545
  
</mark>





  
  

  546
  
 





  
  

  547
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  548
  
    cell





  
  

  549
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  550
  
</mark>





  
  

  551
  
 and 





  
  

  552
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  553
  
    neutrophil





  
  

  554
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  555
  
</mark>





  
  

  556
  
 counts, and 





  
  

  557
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  558
  
    blood





  
  

  559
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  560
  
</mark>





  
  

  561
  
 





  
  

  562
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  563
  
    sugar





  
  

  564
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  565
  
</mark>





  
  

  566
  
, 





  
  

  567
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  568
  
    triglyceride





  
  

  569
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  570
  
</mark>





  
  

  571
  
, and 





  
  

  572
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  573
  
    low





  
  

  574
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  575
  
</mark>





  
  

  576
  
-





  
  

  577
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  578
  
    density





  
  

  579
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  580
  
</mark>





  
  

  581
  
 





  
  

  582
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  583
  
    lipoprotein





  
  

  584
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  585
  
</mark>





  
  

  586
  
 





  
  

  587
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  588
  
    cholesterol





  
  

  589
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  590
  
</mark>





  
  

  591
  
 levels were found to be 





  
  

  592
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  593
  
    elevated





  
  

  594
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  595
  
</mark>





  
  

  596
  
, and the patient's 





  
  

  597
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  598
  
    potassium





  
  

  599
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  600
  
</mark>





  
  

  601
  
 level was 





  
  

  602
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  603
  
    decreased





  
  

  604
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  605
  
</mark>





  
  

  606
  
 to 





  
  

  607
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  608
  
    2.8





  
  

  609
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  610
  
</mark>





  
  

  611
  
 mEq/L.</br>The patient's 





  
  

  612
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  613
  
    lactate





  
  

  614
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  615
  
</mark>





  
  

  616
  
 





  
  

  617
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  618
  
    dehydrogenase





  
  

  619
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  620
  
</mark>





  
  

  621
  
 (





  
  

  622
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  623
  
    468





  
  

  624
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  625
  
</mark>





  
  

  626
  
 





  
  

  627
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  628
  
    IU/L





  
  

  629
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  630
  
</mark>





  
  

  631
  
), 





  
  

  632
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  633
  
    beta





  
  

  634
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  635
  
</mark>





  
  

  636
  
-





  
  

  637
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  638
  
    D





  
  

  639
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  640
  
</mark>





  
  

  641
  
 





  
  

  642
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  643
  
    glucan





  
  

  644
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  645
  
</mark>





  
  

  646
  
 (





  
  

  647
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  648
  
    370.8





  
  

  649
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  650
  
</mark>





  
  

  651
  
 





  
  

  652
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  653
  
    pg/mL





  
  

  654
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  655
  
</mark>





  
  

  656
  
), 





  
  

  657
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  658
  
    ACTH





  
  

  659
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  660
  
</mark>





  
  

  661
  
 (





  
  

  662
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  663
  
    354.1





  
  

  664
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  665
  
</mark>





  
  

  666
  
 





  
  

  667
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  668
  
    pg/mL





  
  

  669
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  670
  
</mark>





  
  

  671
  
), and 





  
  

  672
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  673
  
    cortisol





  
  

  674
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  675
  
</mark>





  
  

  676
  
 (





  
  

  677
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  678
  
    49.1





  
  

  679
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  680
  
</mark>





  
  

  681
  
 





  
  

  682
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  683
  
    μg/dL





  
  

  684
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  685
  
</mark>





  
  

  686
  
) levels were also 





  
  

  687
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  688
  
    elevated





  
  

  689
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  690
  
</mark>





  
  

  691
  
.</br>The patient's 





  
  

  692
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  693
  
    serum





  
  

  694
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  695
  
</mark>





  
  

  696
  
 was 





  
  

  697
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  698
  
    negative





  
  

  699
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  700
  
</mark>





  
  

  701
  
 for 





  
  

  702
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  703
  
    aspergillus





  
  

  704
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  705
  
</mark>





  
  

  706
  
, 





  
  

  707
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  708
  
    candida





  
  

  709
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  710
  
</mark>





  
  

  711
  
, and 





  
  

  712
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  713
  
    cryptococcus





  
  

  714
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  715
  
</mark>





  
  

  716
  
 





  
  

  717
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  718
  
    antigens





  
  

  719
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  720
  
</mark>





  
  

  721
  
; a 





  
  

  722
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  723
  
    cytomegalovirus





  
  

  724
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  725
  
</mark>





  
  

  726
  
 





  
  

  727
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  728
  
    pp65





  
  

  729
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  730
  
</mark>





  
  

  731
  
 





  
  

  732
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  733
  
    antigenemia





  
  

  734
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  735
  
</mark>





  
  

  736
  
 





  
  

  737
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  738
  
    test





  
  

  739
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  740
  
</mark>





  
  

  741
  
 also yielded a 





  
  

  742
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  743
  
    negative





  
  

  744
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  745
  
</mark>





  
  

  746
  
 result.</br>These data suggested that the increased production of ACTH by the tumor, along with the progression of the disease, had promoted the elevation of the patient's serum levels of ACTH and cortisol.</br>





  
  

  747
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  748
  
    Computed





  
  

  749
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  750
  
</mark>





  
  

  751
  
 





  
  

  752
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  753
  
    tomography





  
  

  754
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  755
  
</mark>





  
  

  756
  
 (





  
  

  757
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  758
  
    CT





  
  

  759
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  760
  
</mark>





  
  

  761
  
) revealed the 





  
  

  762
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  763
  
    progression





  
  

  764
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  765
  
</mark>





  
  

  766
  
 





  
  

  767
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  768
  
    of





  
  

  769
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  770
  
</mark>





  
  

  771
  
 





  
  

  772
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  773
  
    the





  
  

  774
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  775
  
</mark>





  
  

  776
  
 





  
  

  777
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  778
  
    disease





  
  

  779
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  780
  
</mark>





  
  

  781
  
 in the both 





  
  

  782
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  783
  
    thymic





  
  

  784
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  785
  
</mark>





  
  

  786
  
 and 





  
  

  787
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  788
  
    metastatic





  
  

  789
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  790
  
</mark>





  
  

  791
  
 





  
  

  792
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  793
  
    bone





  
  

  794
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  795
  
</mark>





  
  

  796
  
 





  
  

  797
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  798
  
    lesions





  
  

  799
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  800
  
</mark>





  
  

  801
  
, along with the 





  
  

  802
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  803
  
    multiple





  
  

  804
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  805
  
</mark>





  
  

  806
  
 





  
  

  807
  
<mark class="entity" style="background: #ffdfba; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  808
  
    ground





  
  

  809
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Texture</span>





  
  

  810
  
</mark>





  
  

  811
  
-





  
  

  812
  
<mark class="entity" style="background: #ffdfba; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  813
  
    glass





  
  

  814
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Texture</span>





  
  

  815
  
</mark>





  
  

  816
  
 





  
  

  817
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  818
  
    opacities





  
  

  819
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  820
  
</mark>





  
  

  821
  
 in 





  
  

  822
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  823
  
    both





  
  

  824
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  825
  
</mark>





  
  

  826
  
 





  
  

  827
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  828
  
    lungs





  
  

  829
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  830
  
</mark>





  
  

  831
  
 (Fig.1, ​2).</br>The patient underwent 





  
  

  832
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  833
  
    bronchoalveolar





  
  

  834
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  835
  
</mark>





  
  

  836
  
 





  
  

  837
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  838
  
    lavage





  
  

  839
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  840
  
</mark>





  
  

  841
  
 (





  
  

  842
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  843
  
    BAL





  
  

  844
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  845
  
</mark>





  
  

  846
  
) in the 





  
  

  847
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  848
  
    right





  
  

  849
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  850
  
</mark>





  
  

  851
  
 





  
  

  852
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  853
  
    B5





  
  

  854
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  855
  
</mark>





  
  

  856
  
 





  
  

  857
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  858
  
    segment





  
  

  859
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  860
  
</mark>





  
  

  861
  
 with 





  
  

  862
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  863
  
    150





  
  

  864
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  865
  
</mark>





  
  

  866
  
 





  
  

  867
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  868
  
    mL





  
  

  869
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  870
  
</mark>





  
  

  871
  
 





  
  

  872
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  873
  
    saline





  
  

  874
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  875
  
</mark>





  
  

  876
  
, and 





  
  

  877
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  878
  
    62.7%





  
  

  879
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  880
  
</mark>





  
  

  881
  
 





  
  

  882
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  883
  
    of





  
  

  884
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  885
  
</mark>





  
  

  886
  
 





  
  

  887
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  888
  
    the





  
  

  889
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  890
  
</mark>





  
  

  891
  
 





  
  

  892
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  893
  
    BAL





  
  

  894
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  895
  
</mark>





  
  

  896
  
 





  
  

  897
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  898
  
    fluid





  
  

  899
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  900
  
</mark>





  
  

  901
  
 





  
  

  902
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  903
  
    was





  
  

  904
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  905
  
</mark>





  
  

  906
  
 





  
  

  907
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  908
  
    recovered





  
  

  909
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  910
  
</mark>





  
  

  911
  
.</br>The 





  
  

  912
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  913
  
    cell





  
  

  914
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  915
  
</mark>





  
  

  916
  
 





  
  

  917
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  918
  
    count





  
  

  919
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  920
  
</mark>





  
  

  921
  
 in the 





  
  

  922
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  923
  
    BAL





  
  

  924
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  925
  
</mark>





  
  

  926
  
 





  
  

  927
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  928
  
    fluid





  
  

  929
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  930
  
</mark>





  
  

  931
  
 was 





  
  

  932
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  933
  
    0.61×105





  
  

  934
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  935
  
</mark>





  
  

  936
  
 





  
  

  937
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  938
  
    per





  
  

  939
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  940
  
</mark>





  
  

  941
  
 





  
  

  942
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  943
  
    mL





  
  

  944
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  945
  
</mark>





  
  

  946
  
, and the 





  
  

  947
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  948
  
    cell





  
  

  949
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  950
  
</mark>





  
  

  951
  
 





  
  

  952
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  953
  
    differentiation





  
  

  954
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  955
  
</mark>





  
  

  956
  
 in the 





  
  

  957
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  958
  
    BAL





  
  

  959
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  960
  
</mark>





  
  

  961
  
 





  
  

  962
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  963
  
    fluid





  
  

  964
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  965
  
</mark>





  
  

  966
  
 was 





  
  

  967
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  968
  
    17.0%





  
  

  969
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  970
  
</mark>





  
  

  971
  
 





  
  

  972
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  973
  
    macrophages





  
  

  974
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  975
  
</mark>





  
  

  976
  
, 





  
  

  977
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  978
  
    81.0%





  
  

  979
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  980
  
</mark>





  
  

  981
  
 





  
  

  982
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  983
  
    lymphocytes





  
  

  984
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  985
  
</mark>





  
  

  986
  
, and 





  
  

  987
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  988
  
    2.0%





  
  

  989
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  990
  
</mark>





  
  

  991
  
 





  
  

  992
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  993
  
    neutrophils





  
  

  994
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  995
  
</mark>





  
  

  996
  
, with a 





  
  

  997
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  998
  
    CD





  
  

  999
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  1000
  
</mark>





  
  

  1001
  
 





  
  

  1002
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1003
  
    4/8





  
  

  1004
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  1005
  
</mark>





  
  

  1006
  
 





  
  

  1007
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1008
  
    ratio





  
  

  1009
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  1010
  
</mark>





  
  

  1011
  
 





  
  

  1012
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1013
  
    of





  
  

  1014
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  1015
  
</mark>





  
  

  1016
  
 





  
  

  1017
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1018
  
    0.57





  
  

  1019
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  1020
  
</mark>





  
  

  1021
  
.</br>





  
  

  1022
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1023
  
    Gram





  
  

  1024
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  1025
  
</mark>





  
  

  1026
  
, 





  
  

  1027
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1028
  
    Ziehl





  
  

  1029
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  1030
  
</mark>





  
  

  1031
  
-





  
  

  1032
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1033
  
    Neelsen





  
  

  1034
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  1035
  
</mark>





  
  

  1036
  
, and 





  
  

  1037
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1038
  
    Grocott





  
  

  1039
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  1040
  
</mark>





  
  

  1041
  
 





  
  

  1042
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1043
  
    staining





  
  

  1044
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  1045
  
</mark>





  
  

  1046
  
 were all 





  
  

  1047
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1048
  
    negative





  
  

  1049
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  1050
  
</mark>





  
  

  1051
  
.</br>A 





  
  

  1052
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1053
  
    polymerase





  
  

  1054
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  1055
  
</mark>





  
  

  1056
  
 





  
  

  1057
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1058
  
    chain





  
  

  1059
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  1060
  
</mark>





  
  

  1061
  
 





  
  

  1062
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1063
  
    reaction





  
  

  1064
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  1065
  
</mark>





  
  

  1066
  
 revealed that the patient's 





  
  

  1067
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1068
  
    BAL





  
  

  1069
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  1070
  
</mark>





  
  

  1071
  
 





  
  

  1072
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1073
  
    fluid





  
  

  1074
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  1075
  
</mark>





  
  

  1076
  
 was 





  
  

  1077
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1078
  
    positive





  
  

  1079
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  1080
  
</mark>





  
  

  1081
  
 for 





  
  

  1082
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1083
  
    Pneumocystis





  
  

  1084
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  1085
  
</mark>





  
  

  1086
  
 





  
  

  1087
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1088
  
    jirovecii





  
  

  1089
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  1090
  
</mark>





  
  

  1091
  
.</br>





  
  

  1092
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1093
  
    PCP





  
  

  1094
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  1095
  
</mark>





  
  

  1096
  
 was diagnosed based on the above results.</br>The patient was treated with 





  
  

  1097
  
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1098
  
    sulfamethoxazole/trimethoprim





  
  

  1099
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span>





  
  

  1100
  
</mark>





  
  

  1101
  
 (





  
  

  1102
  
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1103
  
    12





  
  

  1104
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span>





  
  

  1105
  
</mark>





  
  

  1106
  
 





  
  

  1107
  
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1108
  
    g/day





  
  

  1109
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span>





  
  

  1110
  
</mark>





  
  

  1111
  
) for 





  
  

  1112
  
<mark class="entity" style="background: #ffdfba; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1113
  
    3





  
  

  1114
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Duration</span>





  
  

  1115
  
</mark>





  
  

  1116
  
 





  
  

  1117
  
<mark class="entity" style="background: #ffdfba; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1118
  
    weeks





  
  

  1119
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Duration</span>





  
  

  1120
  
</mark>





  
  

  1121
  
.</br>





  
  

  1122
  
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1123
  
    Anti





  
  

  1124
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span>





  
  

  1125
  
</mark>





  
  

  1126
  
-





  
  

  1127
  
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1128
  
    cortisol





  
  

  1129
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span>





  
  

  1130
  
</mark>





  
  

  1131
  
 





  
  

  1132
  
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1133
  
    therapy





  
  

  1134
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span>





  
  

  1135
  
</mark>





  
  

  1136
  
 with 





  
  

  1137
  
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1138
  
    metyrapone





  
  

  1139
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span>





  
  

  1140
  
</mark>





  
  

  1141
  
 was also initiated at the same time with a 





  
  

  1142
  
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1143
  
    small





  
  

  1144
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span>





  
  

  1145
  
</mark>





  
  

  1146
  
 





  
  

  1147
  
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1148
  
    dose





  
  

  1149
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span>





  
  

  1150
  
</mark>





  
  

  1151
  
 to slowly correct the 





  
  

  1152
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1153
  
    hypercortisolemia





  
  

  1154
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  1155
  
</mark>





  
  

  1156
  
.</br>Intensive 





  
  

  1157
  
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1158
  
    insulin





  
  

  1159
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span>





  
  

  1160
  
</mark>





  
  

  1161
  
 therapy, 





  
  

  1162
  
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1163
  
    potassium





  
  

  1164
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span>





  
  

  1165
  
</mark>





  
  

  1166
  
 supplementation were initiated, while 





  
  

  1167
  
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1168
  
    cefazolin





  
  

  1169
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span>





  
  

  1170
  
</mark>





  
  

  1171
  
 was administered to treat 





  
  

  1172
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1173
  
    cellulitis





  
  

  1174
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  1175
  
</mark>





  
  

  1176
  
 of the 





  
  

  1177
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1178
  
    left





  
  

  1179
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  1180
  
</mark>





  
  

  1181
  
 





  
  

  1182
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1183
  
    lower





  
  

  1184
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  1185
  
</mark>





  
  

  1186
  
 





  
  

  1187
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1188
  
    leg





  
  

  1189
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  1190
  
</mark>





  
  

  1191
  
.</br>The patient's 





  
  

  1192
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1193
  
    PCP





  
  

  1194
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  1195
  
</mark>





  
  

  1196
  
 fully improved without the 





  
  

  1197
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1198
  
    exacerbation





  
  

  1199
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  1200
  
</mark>





  
  

  1201
  
 of his 





  
  

  1202
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1203
  
    respiratory





  
  

  1204
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  1205
  
</mark>





  
  

  1206
  
 





  
  

  1207
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1208
  
    status





  
  

  1209
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  1210
  
</mark>





  
  

  1211
  
.</br>Thereafter, we continued to administer 





  
  

  1212
  
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1213
  
    sulfamethoxazole/trimethoprim





  
  

  1214
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span>





  
  

  1215
  
</mark>





  
  

  1216
  
 at a 





  
  

  1217
  
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1218
  
    prophylactic





  
  

  1219
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span>





  
  

  1220
  
</mark>





  
  

  1221
  
 





  
  

  1222
  
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1223
  
    dose





  
  

  1224
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span>





  
  

  1225
  
</mark>





  
  

  1226
  
.</br>The 





  
  

  1227
  
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1228
  
    metyrapone





  
  

  1229
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span>





  
  

  1230
  
</mark>





  
  

  1231
  
 dosage was gradually increased from 





  
  

  1232
  
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1233
  
    250





  
  

  1234
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span>





  
  

  1235
  
</mark>





  
  

  1236
  
 





  
  

  1237
  
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1238
  
    mg/day





  
  

  1239
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span>





  
  

  1240
  
</mark>





  
  

  1241
  
, and the 





  
  

  1242
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1243
  
    blood





  
  

  1244
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  1245
  
</mark>





  
  

  1246
  
 





  
  

  1247
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1248
  
    cortisol





  
  

  1249
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  1250
  
</mark>





  
  

  1251
  
 value was observed to 





  
  

  1252
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1253
  
    decline





  
  

  1254
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  1255
  
</mark>





  
  

  1256
  
 





  
  

  1257
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1258
  
    slowly





  
  

  1259
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  1260
  
</mark>





  
  

  1261
  
 (Fig.3).</br>In order to prevent hypocortisolemia, the patient was 





  
  

  1262
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1263
  
    temporarily





  
  

  1264
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  1265
  
</mark>





  
  

  1266
  
 treated with 





  
  

  1267
  
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1268
  
    hydrocortisone





  
  

  1269
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span>





  
  

  1270
  
</mark>





  
  

  1271
  
.</br>After an improvement of his 





  
  

  1272
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1273
  
    left





  
  

  1274
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  1275
  
</mark>





  
  

  1276
  
 





  
  

  1277
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1278
  
    lower





  
  

  1279
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  1280
  
</mark>





  
  

  1281
  
 





  
  

  1282
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1283
  
    leg





  
  

  1284
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  1285
  
</mark>





  
  

  1286
  
 





  
  

  1287
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1288
  
    cellulitis





  
  

  1289
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  1290
  
</mark>





  
  

  1291
  
, 





  
  

  1292
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1293
  
    PCP





  
  

  1294
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  1295
  
</mark>





  
  

  1296
  
, and 





  
  

  1297
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1298
  
    hyperglycemia





  
  

  1299
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  1300
  
</mark>





  
  

  1301
  
, the patient underwent 





  
  

  1302
  
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1303
  
    laminectomy





  
  

  1304
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span>





  
  

  1305
  
</mark>





  
  

  1306
  
 and 





  
  

  1307
  
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1308
  
    radiation





  
  

  1309
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span>





  
  

  1310
  
</mark>





  
  

  1311
  
 





  
  

  1312
  
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1313
  
    therapy





  
  

  1314
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span>





  
  

  1315
  
</mark>





  
  

  1316
  
 for 





  
  

  1317
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1318
  
    spinal





  
  

  1319
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  1320
  
</mark>





  
  

  1321
  
 





  
  

  1322
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1323
  
    cord





  
  

  1324
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  1325
  
</mark>





  
  

  1326
  
 





  
  

  1327
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1328
  
    compression





  
  

  1329
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  1330
  
</mark>





  
  

  1331
  
, which had been caused by a 





  
  

  1332
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1333
  
    metastatic





  
  

  1334
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  1335
  
</mark>





  
  

  1336
  
 





  
  

  1337
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1338
  
    spinal





  
  

  1339
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  1340
  
</mark>





  
  

  1341
  
 





  
  

  1342
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1343
  
    tumor





  
  

  1344
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  1345
  
</mark>





  
  

  1346
  
.</br>





  
  

  1347
  
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1348
  
    Octreotide





  
  

  1349
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span>





  
  

  1350
  
</mark>





  
  

  1351
  
 therapy was initiated, and he was 





  
  

  1352
  
<mark class="entity" style="background: #77c5d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1353
  
    discharged





  
  

  1354
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Clinical_event</span>





  
  

  1355
  
</mark>





  
  

  1356
  
 on the 





  
  

  1357
  
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1358
  
    68th





  
  

  1359
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span>





  
  

  1360
  
</mark>





  
  

  1361
  
 





  
  

  1362
  
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  1363
  
    day





  
  

  1364
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span>





  
  

  1365
  
</mark>





  
  

  1366
  
 of hospitalization.</br></div>





  
  

  1367
  
    </body>





  
  

  1368
  
    </html>





  
  

  1369